Mostrar el registro sencillo del ítem
β-Cyclodextrins as affordable antivirals to treat coronavirus infection
dc.contributor.author | Raïch Regué, Dalia | |
dc.contributor.author | Tenorio, Raquel | |
dc.contributor.author | Fernández de Castro, Isabel | |
dc.contributor.author | Tarrés Freixas, Ferrán | |
dc.contributor.author | Sachse, Martín | |
dc.contributor.author | Perez Zsolt, Daniel | |
dc.contributor.author | Muñoz Basagoiti, Jordana | |
dc.contributor.author | Fernández Sánchez, Sara Y | |
dc.contributor.author | Gallemí, Marçal | |
dc.contributor.author | Fernández Oliva, Alberto | |
dc.contributor.author | Gabaldón, José Antonio | |
dc.contributor.author | Casas, Josefina | |
dc.contributor.author | Roca, Nuria | |
dc.contributor.author | Cantero, Guillermo | |
dc.contributor.author | Pérez, Mónica | |
dc.contributor.author | Usai, Carla | |
dc.contributor.author | Lorca Oró, Cristina | |
dc.contributor.author | Vergara Alert, Julia | |
dc.contributor.author | Segalés, Joaquim | |
dc.contributor.author | Carrillo, Jorge | |
dc.contributor.author | Blanco, Julia | |
dc.contributor.author | Bonaventura Clotet, Sala | |
dc.contributor.author | Cerón Carrasco, José Pedro | |
dc.contributor.author | Izquierdo Useros, Nuria | |
dc.contributor.author | Risco, Cristina | |
dc.contributor.author | Ortega González, Paula | |
dc.contributor.author | Núñez Delicado, Estrella | |
dc.date.accessioned | 2024-07-09T08:09:16Z | |
dc.date.available | 2024-07-09T08:09:16Z | |
dc.date.issued | 2023-06-06 | |
dc.identifier.citation | Raïch-Regué D, Tenorio R, Fernández de Castro I, Tarrés-Freixas F, Sachse M, Perez-Zsolt D, Muñoz-Basagoiti J, Fernández-Sánchez SY, Gallemí M, Ortega-González P, Fernández-Oliva A, Gabaldón JA, Nuñez-Delicado E, Casas J, Roca N, Cantero G, Pérez M, Usai C, Lorca-Oró C, Alert JV, Segalés J, Carrillo J, Blanco J, Clotet Sala B, Cerón-Carrasco JP, Izquierdo-Useros N, Risco C. β-Cyclodextrins as affordable antivirals to treat coronavirus infection. Biomed Pharmacother. 2023 Aug;164:114997. doi: 10.1016/j.biopha.2023.114997. Epub 2023 Jun 8. PMID: 37311279; PMCID: PMC10247892. | es |
dc.identifier.isbn | 0753-3322 | |
dc.identifier.uri | http://hdl.handle.net/10952/7958 | |
dc.description.abstract | The SARS-CoV-2 pandemic made evident that there are only a few drugs against coronavirus. Here we aimed to identify a cost-effective antiviral with broad spectrum activity and high safety profile. Starting from a list of 116 drug candidates, we used molecular modelling tools to rank the 44 most promising inhibitors. Next, we tested their efficacy as antivirals against α and β coronaviruses, such as the HCoV-229E and SARS-CoV-2 variants. Four drugs, OSW-1, U18666A, hydroxypropyl-β-cyclodextrin (HβCD) and phytol, showed in vitro antiviral activity against HCoV-229E and SARS-CoV-2. The mechanism of action of these compounds was studied by transmission electron microscopy and by fusion assays measuring SARS-CoV-2 pseudoviral entry into target cells. Entry was inhibited by HβCD and U18666A, yet only HβCD inhibited SARS-CoV-2 replication in the pulmonary Calu-3 cells. Compared to the other cyclodextrins, β-cyclodextrins were the most potent inhibitors, which interfered with viral fusion via cholesterol depletion. β-cyclodextrins also prevented infection in a human nasal epithelium model ex vivo and had a prophylactic effect in the nasal epithelium of hamsters in vivo. All accumulated data point to β-cyclodextrins as promising broad-spectrum antivirals against different SARS-CoV-2 variants and distant alphacoronaviruses. Given the wide use of β-cyclodextrins for drug encapsulation and their high safety profile in humans, our results support their clinical testing as prophylactic antivirals. | es |
dc.language.iso | en | es |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | SARS-CoV-2 | es |
dc.subject | COVID-19 | es |
dc.subject | Coronavirus | es |
dc.subject | Antiviral | es |
dc.subject | Drug repurposing | es |
dc.subject | Cyclodextrin | es |
dc.subject | β-cyclodextrin | es |
dc.title | β-Cyclodextrins as affordable antivirals to treat coronavirus infection | es |
dc.type | article | es |
dc.rights.accessRights | openAccess | es |
dc.relation.projectID | PID2020-117145RB-I00, RTI2018-094445-B100, EU HORIZON-HLTH-2021-CORONA-01 (grant 101046118) | es |
dc.journal.title | Biomedicine & Pharmacotherapy | es |
dc.volume.number | 164 | es |
dc.issue.number | 114997 | es |
dc.description.discipline | Farmacia | es |
dc.description.discipline | Medicina | es |
dc.identifier.doi | 10.1016/j.biopha.2023.114997 | es |